Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental advance in control of acid secretion over the delayed-release proton pump inhibitors. Vonoprazan (a new potassium-competitive acid blocker) displays more potent and extended 24 h acid suppression and preliminary Japanese trials translate this into meaningful clinical benefits in gastro-esophageal reflux disease and Helicobacter pylori eradication. We review the vonoprazan information to date and the indications, benefits, and concerns of more effective therapeutic control of acid secretion.

• Publication year

  2015

• Venue

  Clinical and Translational Gastroenterology

• Publication date

  2015-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/ctg.2015.39PMID 26513137PMCID 4816037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

  2015cited by this paper
• Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

  2015cited by this paper
• High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

  2015cited by this paper
• Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

  2015cited by this paper
• Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients.

  2014cited by this paper
• Prescribing Proton Pump Inhibitors

  2012cited by this paper
• Acid suppression for reflux disease: "off-the-peg" or a tailored approach?

  2012cited by this paper
• Poor effectiveness of proton pump inhibitors in non‐erosive reflux disease: the truth in the end!

  2012cited by this paper
• The risks of PPI therapy

  2012cited by this paper
• Novel Approaches to Inhibition of Gastric Acid Secretion

  2010cited by this paper
• Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.

  2010cited by this paper
• The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.

  2010cited by this paper
• Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.

  2010cited by this paper
• Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

  2010cited by this paper
• Evolving issues in the management of reflux disease?

  2009cited by this paper
• Management of heartburn not responding to proton pump inhibitors

  2009cited by this paper
• Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer.

  2009cited by this paper
• Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group

  2009cited by this paper
• Control of 24-hour Intragastric Acidity With Morning Dosing of Immediate-release and Delayed-release Proton Pump Inhibitors in Patients With GERD

  2009cited by this paper
• The role of proton pump inhibitors in the management of upper gastrointestinal bleeding.

  2009cited by this paper
• Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

  2009cited by this paper
• Pharmacology of proton pump inhibitors

  2008cited by this paper
• A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

  2008cited by this paper
• Proton pump inhibitors: the beginning of the end or the end of the beginning?

  2008cited by this paper
• Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple Therapy

  2007cited by this paper
• A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

  2007cited by this paper
• Acid Suppression Therapy: Where Do We Go from Here?

  2006cited by this paper
• Review article: acid‐related disease – what are the unmet clinical needs?

  2006cited by this paper
• The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus

  2006cited by this paper
• Review article: the clinical pharmacology of proton pump inhibitors

  2006cited by this paper
• Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005

  2005cited by this paper
• Are there unmet needs in acid suppression?

  2004cited by this paper
• The Effects of Nocturnal Acid Breakthrough on Helicobacter pylori Eradication

  2002cited by this paper
• Personal review: alarmism or legitimate concerns about long‐term suppression of gastric acid secretion?

  2000cited by this paper
• Importance of pH control in the management of GERD.

  1999cited by this paper
• A review of the Status of Omeprazole: The Handbury Workshop

  1995cited by this paper
• pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.

  1993cited by this paper
• Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

  1992cited by this paper

• A REVIEW OF PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF GERD, 2015-2025

  2026cites this paper
• PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases

  2026cites this paper
• Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.

  2025cites this paper
• Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial

  2025cites this paper
• First regional consensus on the management of Helicobacter pylori infection in the Middle East

  2025cites this paper
• Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search

  2025cites this paper
• Antibiotic heteroresistance: an important factor in the failure of Helicobacter Pylori eradication

  2025cites this paper
• Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker

  2025cites this paper
• Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease

  2025cites this paper
• American Foregut Society White Paper Report on the Use of Potassium-Competitive Acid Blockers in the Treatment of Gastroesophageal Reflux Disease

  2025cites this paper
• Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología

  2024cites this paper
• The Complexity of Mucosal Damage in Gastroesophageal Airway Reflux Disease: A Molecular Perspective

  2024cites this paper
• Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials

  2024cites this paper
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

  2024cites this paper
• RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis

  2024cites this paper
• P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis

  2024cites this paper
• Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología.

  2024cites this paper
• Design of vonoprazan pyrazole derivatives as potential reversible inhibitors of gastric proton pump: An in silico molecular docking study

  2024cites this paper
• Editorial: pharmacokinetic and pharmacodynamic model for vonoprazan—a step forward to precision medicine

  2023cites this paper
• Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial

  2023cites this paper
• 위산분비 억제제의 역사 및 약리기전

  2023cites this paper
• Review of the clinical development of fexuprazan for gastroesophageal reflux–related disease

  2023cites this paper
• Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review.

  2023cites this paper
• Plants with potential anti-ulcerogenic activity and possible mechanism of actions based on their phyto-constitutional profile

  2022cites this paper
• Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells

  2022cites this paper
• GERD-related chronic cough: Possible mechanism, diagnosis and treatment

  2022cites this paper
• Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

  2022cites this paper
• Chromatographic fractionation and molecular docking of bioactive component from the leaves of Solanum nigrum for binding affinity with proton pump to inhibit gastric acid secretion

  2022cites this paper
• Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

  2022cites this paper
• The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

  2022cites this paper
• A population PK–PD model of YH4808, a novel P‐CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808

  2022cites this paper
• Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

  2022cites this paper
• Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats

  2022cites this paper
• The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD)

  2022cites this paper
• Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data

  2022cites this paper
• Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

  2021cites this paper
• Evaluation and Management of Patients with PPI-Refractory Heartburn

  2021cites this paper
• Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders

  2021cites this paper
• Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies

  2021cites this paper
• Vonoprazan for treatment of gastroesophageal reflux disease: Research advances

  2021cites this paper
• Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

  2021cites this paper
• Design, Synthesis and Pharmacological Evaluation of Novel Imidazopyridine Analogues as Proton Pump Antagonist

  2020cites this paper
• Refractory Gastroesophageal Reflux Disease and Functional Heartburn.

  2020cites this paper
• Pharmacologic treatment of GERD: Where we are now, and where are we going?

  2020cites this paper
• Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility

  2020cites this paper
• Design and Synthesis of Novel Imidazopyridine Analogues and Evaluation as H+/K+-ATPase Antagonist

  2020cites this paper
• Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.

  2020cites this paper
• Gastrointestinal pharmacology: practical tips for the esophagologist

  2020cites this paper
• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

  2019cites this paper
• Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects

  2019influential citation
• The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.

  2019cites this paper
• Gastroesophageal Reflux Disease

  2019cites this paper
• THE PHYSIOLOGICAL ASPECTS OF EFFECTIVE AND SAFE PROTON PUMP INHIBITOR THERAPY FOR ACID SUPPRESSION IN QUETTA

  2019cites this paper
• Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan

  2018cites this paper
• Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects

  2018cites this paper
• Proton pump inhibitors for chronic obstructive pulmonary disease.

  2018cites this paper
• Non-variceal upper gastrointestinal bleeding

  2018cites this paper
• Long Term Use of Proton Pump Inhibitors: Where to Draw the Line

  2018cites this paper
• Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks

  2018cites this paper
• Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?

  2018cites this paper
• Potent Acid Suppression with PPIs and P-CABs: What’s New?

  2018cites this paper
• Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease

  2018cites this paper
• Recent advances in Barrett's esophagus

  2018cites this paper
• Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients

  2017cites this paper
• Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease.

  2017cites this paper
• REVIEW ON IMIDAZOPYRIDINE DERIVATIVES AS POTENT REVERSIBLE INHIBITORS OF THE GASTRIC H + , K + -ATPASE

  2017cites this paper
• Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease

  2017cites this paper
• Molecular Pathogenesis and Signal Transduction by Helicobacter pylori

  2017cites this paper
• A fruitful Discovery of proton pump inhibitors and its future

  2017cites this paper
• Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.

  2017cites this paper
• Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)

  2016cites this paper
• Sustained Acid Suppression by Potassium-Competitive Acid Blocker (P-CAB) May Be An Attractive Treatment Candidate for Patients with Eosinophilic Esophagitis

  2016cites this paper
• The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.

  2016cites this paper
• A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori

  2016cites this paper
• Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

  2016cites this paper
• Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.

  2016cites this paper
• Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression

  2016cites this paper
• Pharmacological Options Beyond Proton Pump Inhibitors in Children with Gastroesophageal Reflux Disease

  2016influential citation
• Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

  2016cites this paper
• Response to Ishimura et al.

  2016cites this paper
• Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

  2016cites this paper
• Editorial: towards extended acid suppression – the search continues

  2015cites this paper